Table 1 Baseline cohort characteristics according to cART initiation: cART resumption after transient treatment started during PHI versus cART initiation during CHI
cART resumption after transient ART during PHI | cART initiation during CHI | p value | |
|---|---|---|---|
N = 136 | N = 377 | ||
Sex, % (n) | |||
Male | 80 (107) | 85 (320) | 0.2 |
Age at enrolment | |||
Median (IQR), years | 37 (31–44) | 36 (30–43) | 0.2 |
Transmission group, % (n)** | 0.2 | ||
Homosexual male | 64 (79) | 74 (268) | |
Heterosexual male | 14 (17) | 11 (39) | |
Female | 22 (28) | 15 (56) | |
Place of birth, % (n) | 0.06 | ||
France | 80 (107) | 87 (327) | |
Sub-Saharan Africa & other | 20 (26) | 13 (48) | |
Education, % (n) | 0.06 | ||
Primary | 11 (14) | 9 (32) | |
Secondary | 34 (44) | 46 (171) | |
University | 55 (72) | 45 (169) | |
Presence of baseline genotypic resistance % (n) | 13 (10) | 14 (50) | 0.2 |
HIV subtype B, % n | 79 (104) | 77 (280) | 0.5 |
HIV tropism, % (n)* | 0.5 | ||
CCR5-tropic | 89 (64) | 86 (274) | |
CXCR4-tropic or dual X4/DM | 11 (8) | 14 (43) | |
Hepatitis C co-infection, % (n) | 1.4 (5) | 0.8 (1) | 0.6 |
Active smoking | 40 (51) | 43 (157) | 0.5 |
CD4 cell count at PHI diagnosis | |||
Median (IQR) cells/mm3 | 473 (323–597) | 544 (420–697) | <0.001 |
HIV load at PHI diagnosis | |||
Median (IQR) log10c/mL | 5.4 (4.9-5.9) | 4.9 (4.2-5.4) | <0.001 |